Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00118261
Recruitment Status : Completed
First Posted : July 11, 2005
Last Update Posted : September 3, 2012
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Smitha Krishnamurthi, Case Comprehensive Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : January 2011
  Actual Study Completion Date : January 2011